Thanks Hulk. Yes one hand, you have the excellent results of leonlimab, close to approval in combo mdr2+, with so,many other possibilities, including a possible phase 3 mono pivotal coming this year, on the other hand the company is limping along financially and has had to sell a lot of shares to get here without giving away the goose to BP; the process has exhausted some. It is sad the market cap is less than the money put into getting leonlimab to this point, but I believe with the BLA submission, everything changes, starting with the balance sheet. Isn’t that the point, once the fda says yes we have everything for the review, that current product capitalization can be included in the balance sheet?